Vicarious Surgical (RBOT) investor relations material

Company vision and market opportunity

• Focuses on developing a minimally invasive robotic surgical system to address limitations of current platforms, especially in adaptability and ease of use.

• Targets procedures beyond prostatectomy, where current robotic adoption is low due to system rigidity and limited access.

• Initial market entry is ventral hernia repair, chosen to showcase unique intra-abdominal access and visualization capabilities.

• Sees opportunity in the 82% of U.S. surgical procedures not currently performed robotically, aiming to capture even a small share for significant revenue.

• Differentiates from competitors by not directly targeting existing robotic market share but focusing on untapped procedural segments.

Technology and product differentiation

• System features decoupled actuators, nine degrees of freedom, and intra-abdominal motion for enhanced dexterity and reach.

• Offers full anatomical reach and 360-degree visualization, including a self-cleaning camera for uninterrupted procedures.

• Single-port entry with two internal arms reduces external crowding and incision sites, improving flexibility and access.

• Protected by patents covering motion, visualization, and future AI/automation capabilities.

• Designed based on direct input from experienced surgeons to overcome limitations of existing systems.

Development progress and commercialization plans

• Transitioned from engineering project to company with robust quality management and traceability systems.

• Achieved first controlled system build in April, followed by a more efficient second build in August.

• Currently at 63% completion of functional and safety requirements, targeting 100% by mid-next year.

• Design lock for the production-equivalent system is planned for late next year, after which regulatory and clinical steps will proceed.

• Main risk identified as market adoption rather than clinical performance, with focus on robust development and verification.